LeonaBio

LeonaBio EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of LeonaBio (LONA) as of Nov 5, 2026 is -102.27 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -100.90 M USD — a change of 1.35% (lower).

EBITDA

-102.27 MUSD

YoY

1.35%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of LeonaBio is 2025 -102.27 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of LeonaBio was 2024 -100.90 M USD. It decreases by 1.35% lower compared to the previous year.

The LeonaBio EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-5.01 M USD
Jan 1, 2019
-5.45 M USD
Jan 1, 2020
-20.00 M USD
Jan 1, 2021
-64.02 M USD
Jan 1, 2022
-104.02 M USD
Jan 1, 2023
-125.47 M USD
Jan 1, 2024
-100.90 M USD
Jan 1, 2025
-102.27 M USD
The LeonaBio EBITDA history
YEAREBITDAYoY
-102.27 MUSD+1.35%
-100.90 MUSD-19.58%
-125.47 MUSD+20.62%
-104.02 MUSD+62.47%
-64.02 MUSD+220.19%
-20.00 MUSD+266.95%
-5.45 MUSD+8.78%
-5.01 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

LeonaBio Stock analysis

What does LeonaBio do? Athira Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, that generates revenue by developing small molecules to restore neuronal health and stop neurodegeneration. The firm utilizes its proprietary ATH platform to target and enhance the activity of a vital neuronal growth factor, creating a pipeline of drugs designed to cross the blood brain barrier for the central nervous system or target the peripheral nervous system. This technology underpins the development of ATH-1017, which is specifically intended for the treatment of neurodegenerative disorders with an initial focus on Alzheimer’s disease. The product aims to improve symptoms in cognitively impaired subjects by enhancing neuronal health and promoting regeneration, serving the medical needs of patients suffering from these conditions. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of LeonaBio is -102.27 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of LeonaBio changed from -100.90 M USD to -102.27 M USD, representing a 1.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) LeonaBio since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s LeonaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — LeonaBio

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — LeonaBio